FDA Recalls Imitrex STATdose Systems Due to Sterility Concerns
GlaxoSmithKline is recalling 10,469 Imitrex STATdose Systems because some syringes may have needles protruding through the shield, compromising sterility.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe rating under the rubric. The hazard involves a potential breach of sterility in a subcutaneous injection device, which is a significant safety concern.
Plain-English summary
The U.S. Food and Drug Administration (FDA) has issued a Class II recall for 10,469 units of Imitrex (sumatriptan) STATdose Systems. The recall was initiated by GlaxoSmithKline, LLC. The affected product is a prescription medication used for subcutaneous injection, specifically the 6 mg sumatriptan succinate formulation. The recall covers Lot C636293 with an expiration date of 06/15.
The reason for the recall is a lack of assurance of sterility. The source text indicates that a small number of the pre-filled syringes may contain needles that protrude through the needle shield. This defect poses a risk to the sterility of the injection system.
The affected products were distributed nationwide. Consumers and healthcare providers should stop using the recalled Imitrex STATdose Systems and contact their healthcare provider or GlaxoSmithKline for further instructions on how to return or dispose of the product.
The recalled product
- Product
- IMITREX (SUMATRIPTAN)
- Brand
- IMITREX
- Manufacturer
- GlaxoSmithKline, LLC.
- Category
- Drug — Injection
- Affected units
- 10,469
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: C636293
- Exp: 06/15
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by GlaxoSmithKline, LLC. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · GlaxoSmithKline, LLC.
See all →- ModerateTIVICAY HIV medication carton mislabeled with incorrect expiration date
FDA (Drugs) · 2024-06-12
- ModerateAnoro Ellipta inhalation powder recalled for failed release testing defect
FDA (Drugs) · 2024-01-03
- ModerateDrug Recall: Tivicay Tablets with Incorrect Expiration Date on Label
FDA (Drugs) · 2022-06-01
- HighGlaxoSmithKline Recalls Ventolin HFA Inhalers Due to Defective Delivery System
FDA (Drugs) · 2017-05-31
- ModerateGlaxoSmithKline Recalls Ventolin Inhalers Due to Defective Delivery System
FDA (Drugs) · 2017-04-12
Same hazard · sterility
See all →- SevereRegeneron Recalls Libtayo Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-08-26
- SeverePrestige Recalls Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns
FDA (Drugs) · 2026-08-19
- SevereROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SevereFDA Recalls ROHTO OPTIC GLOW Eye Drops Over Sterility Concerns
FDA (Drugs) · 2026-07-29